<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02774265</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00065750</org_study_id>
    <nct_id>NCT02774265</nct_id>
  </id_info>
  <brief_title>A Different Approach to Preventing Thrombosis</brief_title>
  <acronym>ADAPT</acronym>
  <official_title>A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to perform a pragmatic randomized controlled trial to compare
      the use of low molecular weight heparin (LMWH, lovenox, enoxaparin) versus acetylsalicylic
      acid (ASA) for venous thromboembolism (VTE) prophylaxis in patients with high-risk lower
      extremity fractures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      To perform a pragmatic randomized controlled trial of the use of low molecular weight heparin
      (LMWH, enoxaparin, lovenox) versus Aspirin (ASA) for VTE prophylaxis in patients with
      high-risk extremity fractures.

      Specific Aims:

        1. To compare the bleeding complication outcomes associated with LMWH versus ASA in
           patients receiving VTE prophylaxis following high-risk lower extremity fractures.

        2. To compare the incidence of clinically important VTE events associated with LMWH versus
           ASA for VTE prophylaxis in patients receiving VTE prophylaxis following high-risk lower
           extremity fractures.

        3. To compare the 6-month treatment costs associated with VTE prophylaxis using either LMWH
           or ASA for high-risk lower extremity fracture patients

      Hypothesis:

        1. Among patients with high risk lower extremity fractures receiving VTE prophylaxis, the
           rate of bleeding complications will be lower for patients receiving ASA compared to
           those receiving LMWH.

        2. Among patients with high risk lower extremity fractures receiving VTE prophylaxis, the
           rate of VTE for patients receiving ASA will be no greater than those receiving LMWH.

        3. Among patients with high risk lower extremity fractures receiving VTE prophylaxis, the
           6-month treatment costs will be lower for patients receiving ASA compared to those
           receiving LMWH.

      Methods/Outcomes:

      A randomized controlled trial will be conducted to assess the use of LMWH versus ASA for VTE
      prophylaxis in patients with high-risk extremity fractures.

      The aim-specific outcomes to be collected are as follows:

        1. A composite of the following major bleeding related complications:

             1. Fatal bleeding into a critical organ (retroperitoneal, intracranial, intraocular,
                intraspinal)

             2. Clinically overt bleed with a &gt; 2g/dL drop in Hb or requiring &gt; 2U transfusion

             3. Wound drainage or hematoma requiring reoperation

             4. Diagnosis of deep surgical site infection

        2. VTE Events defined as a composite of any symptomatic proximal DVT (in the femoral or
           popliteal vessels), or PE (central, segmental or subsegmental). All VTE events will be
           confirmed using multiplanar CT scan or formal venous duplex exam.

        3. Cost of VTE prophylaxis treatment, VTE events and bleeding related complications.

      Data Collection:

      Patients meeting inclusion/exclusion criteria will be prospectively randomized to one of two
      treatment arms. Block randomization will be used. Patients will receive VTE prophylaxis as
      allocated, and followed for their index hospitalization and a 3month period post discharge
      for VTE events and bleeding complications. Outcome data will be prospectively collected
      during index hospitalization, and at 2 weeks and 3 months post discharge, and blind analysis
      and interpretation of results will be performed at 50% and 100% recruitment.

      Data Analysis:

      All data will be reported as mean and standard deviations for continuous variables and
      proportions and percentages for categorical data. Kaplan-Meier survival and Cox proportional
      hazard analysis will be completed for time to VTE and bleeding complication outcomes.
      Sub-group analysis will include Injury Severity Score and fracture location. An independent
      Data Safety and Monitoring Committee will complete interim analysis at 50% recruitment. A
      cost analysis will be conducted using a 6month and lifetime time horizon with a societal
      perspective. Component costs will consist of: VTE prophylaxis costs, unscheduled follow-ups,
      emergency room visit, hospital admission or unscheduled repeat surgical intervention for VTE
      or bleeding complications.

      Study Treatment Arms:

        1. VTE prophylaxis with Enoxaparin 30mg SC BID

        2. VTE prophylaxis with ASA 81mg PO BID
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.</measure>
    <time_frame>90 days</time_frame>
    <description>Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deep Venous Thromboembolism</measure>
    <time_frame>90 days</time_frame>
    <description>DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Embolism Events</measure>
    <time_frame>90 days</time_frame>
    <description>Bases on imaging obtained for symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>VTE prophylaxis with Enoxaparin 30mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VTE prophylaxis with Aspirin 81mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group receiving VTE prophylaxis with ASA 81mg PO BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VTE prophylaxis with Enoxaparin 30mg BID</intervention_name>
    <description>Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
    <arm_group_label>VTE prophylaxis with Enoxaparin 30mg BID</arm_group_label>
    <other_name>Lovenox</other_name>
    <other_name>Low Molecular Weight Heparin (LMWH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VTE prophylaxis with Aspirin 81mg BID</intervention_name>
    <description>Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
    <arm_group_label>VTE prophylaxis with Aspirin 81mg BID</arm_group_label>
    <other_name>ASA (Acetylsalicylic Acid)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients treated at a level-1 trauma center with any one or more of the following
             injuries: Pelvis fracture (operative or non-operative), Acetabulum fracture (operative
             or non-operative), or any operative extremity fracture (proximal to
             metatarsals/carpals)

          -  Age greater than or equal to 18 years old

        Exclusion Criteria:

          -  Patients receiving pre-existing confounding prophylaxis or therapeutic anticoagulation
             (not to include anti-platelet agents) prior to admission or those receiving greater
             than one dose of LMWH since injury

          -  Patients with pre-existing coagulopathy

          -  Patients with a previous history of VTE within the last 6 months

          -  Patients who are pregnant

          -  Patients with CNS or spinal cord injury with potential need for further neurosurgical
             intervention precluding anticoagulation with aspirin

          -  Patients with active bleeding precluding the use of anticoagulation

          -  Impaired creatinine clearance &lt;30ml/min at the time of randomization

          -  History of Heparin Induced Thrombocytopenia or ASA or NSAID allergy

          -  Prisoners

          -  Non-english speaking patients

          -  Patients who have an indication for therapeutic anticoagulation

          -  Patients deemed inappropriate for inclusion in the study by their treating physician.
             Reason must be documented

          -  Patients who would not normally receive VTE prophylaxis for their injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Stein, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>R. Adams Cowley Shock Trauma Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cohen AT, Imfeld S, Markham J, Granziera S. The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. Thromb Res. 2015 Feb;135(2):217-25. doi: 10.1016/j.thromres.2014.11.036. Epub 2014 Dec 13. Review.</citation>
    <PMID>25541030</PMID>
  </reference>
  <reference>
    <citation>Selby R, Geerts WH, Kreder HJ, Crowther MA, Kaus L, Sealey F; D-KAF (Dalteparin in Knee-to-Ankle Fracture) Investigators. A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures. J Orthop Trauma. 2015 May;29(5):224-30. doi: 10.1097/BOT.0000000000000250.</citation>
    <PMID>25900749</PMID>
  </reference>
  <reference>
    <citation>Scolaro JA, Taylor RM, Wigner NA. Venous thromboembolism in orthopaedic trauma. J Am Acad Orthop Surg. 2015 Jan;23(1):1-6. doi: 10.5435/JAAOS-23-01-1.</citation>
    <PMID>25538125</PMID>
  </reference>
  <reference>
    <citation>Gritsiouk Y, Hegsted DA, Schlesinger P, Gardiner SK, Gubler KD. A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients. Am J Surg. 2014 May;207(5):648-51; discussion 651-2. doi: 10.1016/j.amjsurg.2013.12.010. Epub 2014 Jan 30.</citation>
    <PMID>24560359</PMID>
  </reference>
  <reference>
    <citation>Schousboe JT, Brown GA. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. J Bone Joint Surg Am. 2013 Jul 17;95(14):1256-64. doi: 10.2106/JBJS.L.00400.</citation>
    <PMID>23864173</PMID>
  </reference>
  <reference>
    <citation>Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2013 Oct 2;95(19):1801-11. doi: 10.2106/JBJS.L.01328. Review.</citation>
    <PMID>24088973</PMID>
  </reference>
  <reference>
    <citation>Mortazavi SM, Hansen P, Zmistowski B, Kane PW, Restrepo C, Parvizi J. Hematoma following primary total hip arthroplasty: a grave complication. J Arthroplasty. 2013 Mar;28(3):498-503. doi: 10.1016/j.arth.2012.07.033. Epub 2012 Oct 31.</citation>
    <PMID>23122656</PMID>
  </reference>
  <reference>
    <citation>Brakenridge SC, Henley SS, Kashner TM, Golden RM, Paik DH, Phelan HA, Cohen MJ, Sperry JL, Moore EE, Minei JP, Maier RV, Cuschieri J; Inflammation and the Host Response to Injury Investigators. Comparing clinical predictors of deep venous thrombosis versus pulmonary embolus after severe injury: a new paradigm for posttraumatic venous thromboembolism? J Trauma Acute Care Surg. 2013 May;74(5):1231-7; discussion 1237-8. doi: 10.1097/TA.0b013e31828cc9a0.</citation>
    <PMID>23609272</PMID>
  </reference>
  <reference>
    <citation>Sagi HC, Dziadosz D, Mir H, Virani N, Olson C. Obesity, leukocytosis, embolization, and injury severity increase the risk for deep postoperative wound infection after pelvic and acetabular surgery. J Orthop Trauma. 2013 Jan;27(1):6-10. doi: 10.1097/BOT.0b013e31825cf382.</citation>
    <PMID>23263468</PMID>
  </reference>
  <reference>
    <citation>Raphael IJ, Tischler EH, Huang R, Rothman RH, Hozack WJ, Parvizi J. Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty? Clin Orthop Relat Res. 2014 Feb;472(2):482-8. doi: 10.1007/s11999-013-3135-z.</citation>
    <PMID>23817755</PMID>
  </reference>
  <reference>
    <citation>Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother. 2013 Jan;47(1):63-74. doi: 10.1345/aph.1R331. Epub 2013 Jan 16. Review.</citation>
    <PMID>23324504</PMID>
  </reference>
  <reference>
    <citation>Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W, Gofton W, Gross P, Pelet S, Crowther M, MacDonald S, Kim P, Pleasance S, Davis N, Andreou P, Wells P, Kovacs M, Rodger MA, Ramsay T, Carrier M, Vendittoli PA. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013 Jun 4;158(11):800-6. doi: 10.7326/0003-4819-158-11-201306040-00004.</citation>
    <PMID>23732713</PMID>
  </reference>
  <reference>
    <citation>Cossetto DJ, Goudar A, Parkinson K. Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. J Orthop Surg (Hong Kong). 2012 Dec;20(3):341-3.</citation>
    <PMID>23255642</PMID>
  </reference>
  <reference>
    <citation>Vulcano E, Gesell M, Esposito A, Ma Y, Memtsoudis SG, Gonzalez Della Valle A. Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop. 2012 Oct;36(10):1995-2002. doi: 10.1007/s00264-012-1588-4. Epub 2012 Jun 12.</citation>
    <PMID>22684546</PMID>
  </reference>
  <reference>
    <citation>Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011 Dec;19(12):777-8.</citation>
    <PMID>22134210</PMID>
  </reference>
  <reference>
    <citation>Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010 Oct;25(7):1053-60. doi: 10.1016/j.arth.2009.06.021. Epub 2009 Aug 12.</citation>
    <PMID>19679434</PMID>
  </reference>
  <reference>
    <citation>Hill J, Treasure T; Guideline Development Group. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital: summary of the NICE guideline. Heart. 2010 Jun;96(11):879-82. doi: 10.1136/hrt.2010.198275.</citation>
    <PMID>20478866</PMID>
  </reference>
  <reference>
    <citation>Slobogean GP, Lefaivre KA, Nicolaou S, O'Brien PJ. A systematic review of thromboprophylaxis for pelvic and acetabular fractures. J Orthop Trauma. 2009 May-Jun;23(5):379-84. doi: 10.1097/BOT.0b013e3181a5369c. Review.</citation>
    <PMID>19390367</PMID>
  </reference>
  <reference>
    <citation>Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. J Bone Joint Surg Br. 2009 Mar;91(3):388-94. doi: 10.1302/0301-620X.91B3.20820.</citation>
    <PMID>19258618</PMID>
  </reference>
  <reference>
    <citation>Novicoff WM, Brown TE, Cui Q, Mihalko WM, Slone HS, Saleh KJ. Mandated venous thromboembolism prophylaxis: possible adverse outcomes. J Arthroplasty. 2008 Sep;23(6 Suppl 1):15-9. doi: 10.1016/j.arth.2008.04.014. Epub 2008 Jun 13.</citation>
    <PMID>18555656</PMID>
  </reference>
  <reference>
    <citation>Watson HG, Chee YL. Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Rev. 2008 Mar;22(2):107-16. doi: 10.1016/j.blre.2007.11.001. Epub 2008 Jan 15. Review.</citation>
    <PMID>18226435</PMID>
  </reference>
  <reference>
    <citation>Myers DD Jr, Wrobleski SK, Longo C, Bedard PW, Kaila N, Shaw GD, Londy FJ, Rohrer SE, Fex BA, Zajkowski PJ, Meier TR, Hawley AE, Farris DM, Ballard NE, Henke PK, Schaub RG, Wakefield TW. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. Thromb Haemost. 2007 Mar;97(3):400-7.</citation>
    <PMID>17334507</PMID>
  </reference>
  <reference>
    <citation>Slavik RS, Chan E, Gorman SK, de Lemos J, Chittock D, Simons RK, Wing PC, Ho SG. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial. J Trauma. 2007 May;62(5):1075-81; discussion 1081.</citation>
    <PMID>17495705</PMID>
  </reference>
  <reference>
    <citation>Burnett RS, Clohisy JC, Wright RW, McDonald DJ, Shively RA, Givens SA, Barrack RL. Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty. 2007 Apr;22(3):317-24.</citation>
    <PMID>17400085</PMID>
  </reference>
  <reference>
    <citation>Stannard JP, Lopez-Ben RR, Volgas DA, Anderson ER, Busbee M, Karr DK, McGwin GR Jr, Alonso JE. Prophylaxis against deep-vein thrombosis following trauma: a prospective, randomized comparison of mechanical and pharmacologic prophylaxis. J Bone Joint Surg Am. 2006 Feb;88(2):261-6.</citation>
    <PMID>16452735</PMID>
  </reference>
  <reference>
    <citation>Myers DD Jr, Rectenwald JE, Bedard PW, Kaila N, Shaw GD, Schaub RG, Farris DM, Hawley AE, Wrobleski SK, Henke PK, Wakefield TW. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg. 2005 Aug;42(2):329-36.</citation>
    <PMID>16102635</PMID>
  </reference>
  <reference>
    <citation>Steele N, Dodenhoff RM, Ward AJ, Morse MH. Thromboprophylaxis in pelvic and acetabular trauma surgery. The role of early treatment with low-molecular-weight heparin. J Bone Joint Surg Br. 2005 Feb;87(2):209-12.</citation>
    <PMID>15736745</PMID>
  </reference>
  <reference>
    <citation>Jørgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R, Kirchhoff-Jensen R, Kjaer L, Kerbouche N, Leth-Espensen P, Narvestad E, Rasmussen SW, Sloth C, Tørholm C, Wille-Jørgensen P. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res. 2002 Mar 15;105(6):477-80.</citation>
    <PMID>12091045</PMID>
  </reference>
  <reference>
    <citation>Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma. 2002 Jul;53(1):142-64. Review.</citation>
    <PMID>12131409</PMID>
  </reference>
  <reference>
    <citation>Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 2002 Sep 5;347(10):726-30.</citation>
    <PMID>12213943</PMID>
  </reference>
  <reference>
    <citation>Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 2001 Apr;16(3):293-300.</citation>
    <PMID>11307125</PMID>
  </reference>
  <reference>
    <citation>Hak DJ. Prevention of venous thromboembolism in trauma and long bone fractures. Curr Opin Pulm Med. 2001 Sep;7(5):338-43. Review.</citation>
    <PMID>11584186</PMID>
  </reference>
  <reference>
    <citation>Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000 Apr 15;355(9212):1295-302.</citation>
    <PMID>10776741</PMID>
  </reference>
  <reference>
    <citation>Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. J Trauma. 1997 Jan;42(1):100-3.</citation>
    <PMID>9003265</PMID>
  </reference>
  <reference>
    <citation>Lotke PA, Palevsky H, Keenan AM, Meranze S, Steinberg ME, Ecker ML, Kelley MA. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res. 1996 Mar;(324):251-8.</citation>
    <PMID>8595765</PMID>
  </reference>
  <reference>
    <citation>Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 22;308(6923):235-46.</citation>
    <PMID>8054013</PMID>
  </reference>
  <reference>
    <citation>Schumacher WA, Heran CL. Effect of thromboxane receptor antagonists on venous thrombosis in rats. J Pharmacol Exp Ther. 1989 Mar;248(3):1109-15.</citation>
    <PMID>2522985</PMID>
  </reference>
  <reference>
    <citation>Vesterqvist O, Gréen K, Johnsson H. Thromboxane and prostacyclin formation in patients with deep vein thrombosis. Thromb Res. 1987 Feb 15;45(4):393-402.</citation>
    <PMID>3554598</PMID>
  </reference>
  <reference>
    <citation>McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal PS, Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J. 1980 Feb 23;280(6213):514-7.</citation>
    <PMID>6989432</PMID>
  </reference>
  <reference>
    <citation>Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977 Dec 8;297(23):1246-9.</citation>
    <PMID>335247</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2016</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>June 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2018</results_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Deborah Stein</investigator_full_name>
    <investigator_title>Professor of Surgery, Chief of Trauma</investigator_title>
  </responsible_party>
  <keyword>Fracture</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be shared as aggregate data only to protect the identity of individual participants.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02774265/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited inpatients admitted between January 19, 2016 and November 1, 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>VTE Prophylaxis With Enoxaparin 30mg BID</title>
          <description>The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
VTE prophylaxis with Enoxaparin 30mg BID: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
        </group>
        <group group_id="P2">
          <title>VTE Prophylaxis With Aspirin 81mg BID</title>
          <description>The group receiving VTE prophylaxis with ASA 81mg PO BID
VTE prophylaxis with Aspirin 81mg BID: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis is the same as the assignment in Participant Flow</population>
      <group_list>
        <group group_id="B1">
          <title>VTE Prophylaxis With Enoxaparin 30mg BID</title>
          <description>The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
VTE prophylaxis with Enoxaparin 30mg BID: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
        </group>
        <group group_id="B2">
          <title>VTE Prophylaxis With Aspirin 81mg BID</title>
          <description>The group receiving VTE prophylaxis with ASA 81mg PO BID
VTE prophylaxis with Aspirin 81mg BID: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="329"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="20.4"/>
                    <measurement group_id="B2" value="48" spread="18.6"/>
                    <measurement group_id="B3" value="46.7" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.</title>
        <description>Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed</description>
        <time_frame>90 days</time_frame>
        <population>As described in Participant Flow</population>
        <group_list>
          <group group_id="O1">
            <title>VTE Prophylaxis With Enoxaparin 30mg BID</title>
            <description>The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
VTE prophylaxis with Enoxaparin 30mg BID: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
          </group>
          <group group_id="O2">
            <title>VTE Prophylaxis With Aspirin 81mg BID</title>
            <description>The group receiving VTE prophylaxis with ASA 81mg PO BID
VTE prophylaxis with Aspirin 81mg BID: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Bleeding Events as Assessed by the Need for Blood Transfusions and Procedures for Bleeding Complications After Initiation of the Study Medication.</title>
          <description>Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed</description>
          <population>As described in Participant Flow</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deep Venous Thromboembolism</title>
        <description>DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy.</description>
        <time_frame>90 days</time_frame>
        <population>same as flow chart</population>
        <group_list>
          <group group_id="O1">
            <title>VTE Prophylaxis With Enoxaparin 30mg BID</title>
            <description>The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
VTE prophylaxis with Enoxaparin 30mg BID: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
          </group>
          <group group_id="O2">
            <title>VTE Prophylaxis With Aspirin 81mg BID</title>
            <description>The group receiving VTE prophylaxis with ASA 81mg PO BID
VTE prophylaxis with Aspirin 81mg BID: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deep Venous Thromboembolism</title>
          <description>DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy.</description>
          <population>same as flow chart</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Embolism Events</title>
        <description>Bases on imaging obtained for symptoms.</description>
        <time_frame>90 days</time_frame>
        <population>As per flow sheet</population>
        <group_list>
          <group group_id="O1">
            <title>VTE Prophylaxis With Enoxaparin 30mg BID</title>
            <description>The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
VTE prophylaxis with Enoxaparin 30mg BID: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
          </group>
          <group group_id="O2">
            <title>VTE Prophylaxis With Aspirin 81mg BID</title>
            <description>The group receiving VTE prophylaxis with ASA 81mg PO BID
VTE prophylaxis with Aspirin 81mg BID: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Embolism Events</title>
          <description>Bases on imaging obtained for symptoms.</description>
          <population>As per flow sheet</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days post injury</time_frame>
      <desc>Adverse events as described by our IRB reporting protocol include only unexpected adverse events. Since study outcomes like bleeding and venous thromboembolism are expected, measured outcomes, these are not included.</desc>
      <group_list>
        <group group_id="E1">
          <title>VTE Prophylaxis With Enoxaparin 30mg BID</title>
          <description>The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
VTE prophylaxis with Enoxaparin 30mg BID: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
        </group>
        <group group_id="E2">
          <title>VTE Prophylaxis With Aspirin 81mg BID</title>
          <description>The group receiving VTE prophylaxis with ASA 81mg PO BID
VTE prophylaxis with Aspirin 81mg BID: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bryce Haac</name_or_title>
      <organization>University of Maryland Medical Center</organization>
      <phone>410-328-3495</phone>
      <email>bhaac@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

